{
    "nctId": "NCT03140553",
    "briefTitle": "TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer",
    "officialTitle": "TCH (Docetaxel/Carboplatin/Trastuzumab) Versus EC -TH(Epirubicin/Cyclophosphamide Followed by Docetaxe/Trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "HER2-Positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 140,
    "primaryOutcomeMeasure": "pCR",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed HER2 positive invasive breast carcinoma\n* Clinical stage \u2161-\u2162C\n* Eastern Cooperative Oncology Group(ECOG) performance status 0 to 1 within 14 days of study entry\n* Normal (greater than 50%) left ventricular ejection fraction (LVEF) by echocardiography\n* Signed informed consent\n* Adequate organ function within 2 weeks of study entry:\n\nAbsolute neutrophil count \\>1500/mm3, Hgb \\>9.0 g/dl and platelet count \\>100,000/mm3 Total bilirubin \\< upper limit of normal Creatinine \\< 1.5 mg/dL or calculated cranial cruciate ligament (CrCL) \\>50mL/min using the Cockcroft Gault equation serum glutamate oxaloacetate transaminase(SGOT)(AST) or serum glutamic oxaloacetic transaminase(SGPT)(ALT) and Alkaline Phosphatase must be within the range allowing for eligibility\n\n* Patients must be over 18 years old.\n* Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment\n* Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation.\n\nExclusion Criteria:\n\n* Metastatic disease\n* Prior chemotherapy, hormonal therapy, biologic therapy, investigational agent, targeted therapy or radiation therapy for current breast cancer. Patients with history of breast cancer greater than 5 years from initial diagnosis are eligible for the study. Patients may not have received anthracycline-based chemotherapy in the past. Patients with history of ductal carcinoma in situ(DCIS) are eligible if there were treated with surgery alone.\n* History of previous or current malignancy at other sites with the exception of adequately treated carcinoma in-situ of the cervix or basal or squamous cell carcinoma of the skin. Patients with a history of other malignancies, who remain disease free for greater than five years are eligible.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}